Lilly (Eli) (LLY)
NYSEHealth CareDrug Manufacturers - GeneralSnapshot 2026-07-07
$1235.65+2.97%
Close 2026-07-07 · 1-day change
Reading LLY? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track LLY free→NYSEHealth CareDrug Manufacturers - GeneralSnapshot 2026-07-07
Reading LLY? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track LLY free→A long-form read on the 1–3 year hold thesis. Slower and deeper than the daily snapshot — it refreshes only when the evidence moves.
This investment represents a durable compounder with a stable management team. The current thesis state is intact, supported by strong recent financial performance, but the valuation is high compared to peers.
The market has priced in an expensive valuation with a significant premium over peers, reflecting a durable premium. There is an expectations gap indicating that the market anticipates continued strong performance, despite the fragility in earnings quality.
Fundamentals are likely to remain strong in the near term, as management is on track with priorities like expanding access to obesity medicines and increasing manufacturing capacity. However, there is a low probability of a miss, although recent earnings surprises are trending down.
The thesis hinges on the performance of sector bellwethers like JNJ, ABBV, and MRK. If these companies continue to beat earnings and guide higher, it could provide a favorable backdrop for LLY. Conversely, if they start to miss or guide lower, it could negatively impact LLY's momentum.
The outlook for LLY over the next 1 to 3 years depends on sector performance and management execution. Not investment advice.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The latest earnings beat supports the thesis. Regulatory progress for new products also strengthens the outlook. There are no new threats noted.
as of 2026-07-07
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: Earnings results will show how much money they make and how products do.
Confirms one read:Earnings report shows revenue growth above $20 billion for Q2 2026.
Confirms the other:Earnings report shows revenue growth below $18 billion for Q2 2026.
Why it matters: Approval would grow Lilly's obesity treatment options. This would help increase sales.
Confirms:FDA grants approval for orforglipron for obesity in the U.S.
Disproves:The FDA denies or delays the decision on orforglipron.
Why it matters: Strong uptake would demonstrate the success of Lilly's new GLP-1 therapy.
Confirms:Foundayo achieves over $1 billion in sales within the first six months post-launch.
Disproves:Foundayo sales remain below $500 million in the first six months post-launch.
Why it matters: Strong revenue growth would support Lilly's guidance and reflect successful product launches.
Confirms:Q2 2026 revenue growth exceeds 50% year over year.
Disproves:Q2 2026 revenue growth falls below 40% year over year.
Why it matters: Strong growth shows demand is high and the market is working.
Confirms:Mounjaro revenue growth exceeds 60% year over year in Q2 2026.
Disproves:Mounjaro revenue growth falls below 50% year over year in Q2 2026.
Why it matters: Strong sales from these products are key to maintaining overall revenue momentum.
Confirms:Combined revenue from Mounjaro and Zepbound exceeds $13 billion in Q2 2026.
Disproves:Combined revenue from Mounjaro and Zepbound falls below $10 billion in Q2 2026.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.